脑感知synNotch-CAR T细胞在多模型中精准靶向并清除弥漫性中线胶质瘤
该研究将脑限制性synNotch-CAR T细胞平台应用于弥漫性中线胶质瘤(DMG),以 brevican(BCAN)为感知抗原诱导针对EphA2、IL-13Rα2或B7-H3的CAR表达。免疫缺陷与免疫健全DMG模型中,静脉或脑室内输注均可实现肿瘤浸润、持续存在和生存延长;但脑室内递送B7-H3 CAR因非肿瘤CNS低表达而引发致死性神经毒性,提示递送途径影响安全性。
要点
- BCAN门控的synNotch-CAR T细胞可将CAR表达限制于CNS,降低on-target/off-tumor风险。
- 免疫缺陷DMG模型中,单次静脉或脑室内输注B-SYNC T细胞可浸润肿瘤并延长生存。
- 脑室内递送B7-H3 CAR因非肿瘤CNS低表达引发致死性神经毒性,静脉递送更安全。
核心结论
- 脑感知synNotch-CAR T电路是靶向DMG等多种CNS恶性肿瘤的可泛化、可转化策略。
研究设计与样本
- 临床前研究:在免疫缺陷和免疫健全的同基因DMG模型中评估BCAN门控synNotch-CAR T细胞。
- 工程化T细胞电路:BCAN特异性synNotch受体诱导针对EphA2、IL-13Rα2或B7-H3的CAR表达。
主要发现
- 免疫缺陷DMG模型中,单次静脉或脑室内输注B-SYNC电路T细胞导致肿瘤浸润、持续存在、抗肿瘤活性和生存延长。
- 静脉递送BCAN启动的B7-H3或IL-13Rα2 CAR(B-SYNC-B/I)同样改善疗效。
- 脑室内递送B-SYNC-B/I因非肿瘤CNS区域低水平B7-H3表达触发致死性神经毒性。
- 免疫健全同基因DMG模型中,鼠源化BCAN门控B7-H3 CAR(mB-SYNC-B7-H3)经静脉或脑室内递送均实现持久肿瘤清除和再攻击抵抗,未检测到神经毒性。
- synNotch启动的CAR T细胞表现为耗竭减少、活化增强及naïve和干细胞记忆样亚群富集。
临床怎么用
- 静脉递送脑感知synNotch-CAR T细胞可能较脑室内递送具有更低的非肿瘤CNS毒性风险。
- 靶向B7-H3的脑限制性CAR需谨慎评估非肿瘤CNS低表达带来的脱靶毒性。
局限性
- 主要证据来自临床前DMG模型,尚未在人体中验证。
- 脑室内递送B7-H3 CAR在免疫缺陷模型中观察到致死性神经毒性,提示递送途径和靶点选择需进一步优化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diffuse midline glioma (DMG) is a lethal pediatric brain tumor with limited therapeutic options and a poor prognosis. The success of chimeric antigen receptor (CAR) T cell therapy requires both improving T cell tumor infiltration and persistence and reducing the risk of on-target/off-tumor toxicity. Here, we adapted and advanced a brain-restricted CAR T cell platform previously validated in glioblastoma to address the anatomical and biological challenges of DMG. We engineered a T cell circuit in which a brain-specific synthetic Notch (synNotch) receptor recognizing brevican (BCAN) induced CAR expression against EphA2 or IL-13Rα2 ("B-SYNC"), thereby restricting CAR expression to the central nervous system (CNS). In immunodeficient DMG models, a single infusion of intravenous (iv) or intracerebroventricular (icv) B-SYNC circuit T cells led to tumor infiltration, sustained persistence, antitumor activity, and extended survival. An alternative BCAN-primed CAR targeting B7-H3 or IL-13Rα2 ("B-SYNC-B/I") similarly improved therapeutic efficacy when delivered intravenously. However, icv administration triggered fatal neurotoxicity because of low-level B7-H3 expression in nontumor CNS regions, indicating that rapid CNS exposure via icv delivery can amplify off-tumor toxicity. In contrast, in an immunocompetent syngeneic DMG model, both iv and icv delivery of a murinized BCAN-gated B7-H3 CAR (mB-SYNC-B7-H3) achieved durable tumor clearance and resistance to rechallenge without any detectable neurotoxicity. Mechanistically, synNotch-primed CAR T cells exhibited reduced exhaustion, enhanced activation, and enrichment of naïve and stem cell memory-like subsets. These findings demonstrate that brain-sensing synNotch CAR T circuits represent a generalizable and translatable strategy for targeting multiple CNS malignancies, including DMG.
引用
- Lakshmanachetty S, Simic MS, Watchmaker PB, et al. Brain-sensing synNotch-CAR T cells enable precise targeting and clearance of diffuse midline glioma in multiple preclinical models. Sci Transl Med. 2026. PMID: 42950017. doi:10.1126/scitranslmed.aed9994
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。